Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
MeiraGTx Holdings plc completed an acquisition involving Janssen Pharmaceuticals, Inc. for upfront cash purchase price of $25,000,000 (closed 2026-04-15).
- Action
- acquisition
- Counterparty
- Janssen Pharmaceuticals, Inc.
- Consideration
- upfront cash purchase price of $25,000,000
- Closing
- 2026-04-15
Exact text from the filing
to mutations in the RPGR gene (the “RPGR Product”), and other related assets as described in the Asset Purchase Agreement. Buyer agreed to pay an upfront cash purchase price of $25,000,000 to Seller. Additionally, pursuant to and subject to the terms and conditions set forth in the Asset Purchase Agreement, Buyer agreed to pay Seller a one-time, future contingent
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
MeiraGTx Holdings plc entered into Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. valued at $25,000,000 (effective 2026-04-15).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Janssen Pharmaceuticals, Inc.
- Value
- $25,000,000
- Effective
- 2026-04-15
Exact text from the filing
On April 15, 2026 (the “Closing Date”), MeiraGTx Holdings plc (the “Company”) and its wholly-owned subsidiary MeiraGTx Ocular UK Limited, a company incorporated in England and Wales (“MeiraGTx Ocular” and together with the Company, collectively the “Buyer”), entered into and consummated an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Seller”), pursuant to which Seller sold and assigned to Buyer, and Buyer purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) and Janssen (the “UCL License Agreement”), relating to the research, development, manufacture and exploitation of Seller’s gene therapy product for the treatment of X-linked retinitis pigmentosa related to mutations in the RPGR gene (the “RPGR Product”), and other related assets as described in the Asset Purchase Agreement. Buyer agreed to pay an upfront cash purchase price o
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
MeiraGTx Holdings plc terminated Original Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. (effective 2026-04-15).
- Action
- termination
- Agreement
- asset purchase
- Counterparty
- Janssen Pharmaceuticals, Inc.
- Effective
- 2026-04-15
Exact text from the filing
Seller and Buyer entered into a Termination Agreement on April 15, 2026 (the “Termination Agreement”) terminating that certain Asset Purchase Agreement, dated as of December 20, 2023 (the “Original Asset Purchase Agreement”), by and among Seller and the Company and its wholly-owned subsidiary MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), that certain Supply Agreement, dated as of December 20, 2023 by and between MeiraGTx UK II and Seller, and certain other documents related to the Original Asset Purchase Agreement.
View on SEC.gov